Cancer-associated Muscle Mass - Molecular Factors and Exercise Mechanisms

Launched by UNIVERSITY OF COPENHAGEN · Mar 23, 2022

Keywords

ClinConnect Summary

This clinical trial is focused on understanding and addressing a condition called cancer cachexia, which is the unintentional loss of muscle mass and weight that many cancer patients experience. This trial specifically looks at patients with advanced lung cancer and aims to explore the chemical changes in their bodies that lead to muscle loss, how exercise might help improve their muscle function and overall well-being, and the impact of these changes on both patients and their caregivers. By studying muscle and fat tissue from participants, researchers hope to uncover new insights that could lead to better treatments for those affected by this serious condition.

To participate, individuals must be at least 18 years old and have been diagnosed with a specific type of lung cancer that isn’t currently undergoing aggressive treatment. Participants will undergo various assessments to measure their muscle and fat levels, physical performance, and the effects of exercise. The trial is looking for volunteers who are ready to help improve our understanding of cancer cachexia and potentially enhance the quality of life for many patients. If you or a loved one is interested in this study, please discuss it with your healthcare provider for more information.

Gender

ALL

Eligibility criteria

• Inclusion Criteria, WP1+WP2X+WP2:
• • Men and women at or above the age of 18
• • Histological and radiological verified NSCLC (both squamous and adenocarcinoma) st. IIIb/IV stage not eligible to concurrent chemo/radiation therapy as primary treatment
• • Referred for 1st line palliative anticancer therapy (platin based, immunotherapy, combined therapy or TKI), this goes for WP1 + WP2
• • Referred for palliative anticancer therapy (platin based, immunotherapy, combined therapy or TKI), for recurrent cancer, this goes only for WP2X.
• • Having a staging/baseline CT within 4 weeks of initiation of treatment (PET/CT are also allowed), or a baseline scan planned within the first week of treatment.
• • ECOG Performance Status 0-2
• • Having signed the informed consent form
• Exclusion Criteria, WP1+WP2X+WP2:
• • Any other known malignancy requiring active treatment (prior cancer diagnosis is not some exclusion criteria if oncology-treatment is completed)
• • Local palliative radiotherapy as primary treatment
• • ECOG Performance status \> 2
• • Physical disabilities excluding physical testing
• • Inability to understand Danish
• • Inability to understand scoring systems/patient-reported outcome measures
• Inclusion Criteria, WP3:
• • Men and women above the age of 18
• • Histological and radiological verified NSCLC (both squamous and adenocarcinoma) st. IIIb/IV stage
• • ECOG Performance Status 0-2
• • Having signed the informed consent form.
• Exclusion Criteria, WP3:
• • Any other known malignancy requiring active treatment (prior cancer diagnosis is not some exclusion criteria if oncology-treatment is completed)
• • ECOG Performance Status \> 2
• • Physical disabilities excluding physical testing
• • Inability to understand Danish
• • Inability to understand scoring systems/patient-reported outcome measures